You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Drug Formulary
About the Drug Formulary Email Drug Formulary Team

pemetrexed

( peh-meh-TREX-edd )
Funding:
New Drug Funding Program
  • Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
  • Pemetrexed - Non-Small Cell Lung Cancer (following Crizotinib)
  • Pemetrexed - Advanced Malignant Pleural Mesothelioma (MPM)
  • Pemetrexed - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Pemetrexed - Maintenance Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
... Show more tags
Other Name(s): Alimta® (multiple brands available)
Appearance: Colourless solution mixed into larger bags of fluids

Drug Monograph

Nov 2017
Table of Contents
Eligibility Forms
pdf download Pemetrexed - Advanced Malignant Pleural Mesothelioma (MPM) pdf download Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer pdf download Pemetrexed - Maintenance Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) pdf download Pemetrexed - Non-Small Cell Lung Cancer (following Crizotinib) pdf download Pemetrexed - Non-Small Cell Lung Cancer (Second or Subsequent Line)

Patient Info Sheet

May 2018

What it is used for

• For treating some types of cancer arising either from the lung or the inside lining of the chest cavity



You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration